

Associate editor: G.F. Baxter

Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis

R. Schulz^{a,*}, T. Rassaf^b, P. B. Massion^c, M. Kelm^b, J. -L. Balligand^c

^a*Institut für Pathophysiologie, Zentrum für Innere Medizin des Universitätsklinikums Essen, Germany*

^b*Klinik für Kardiologie, Pulmologie, Angiologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany*

^c*Unit of Pharmacology and Therapeutics, FATH 5349, Université Catholique de Louvain, 1200 Brussels, Belgium*

Abstract

Nitric oxide synthases (NOS) are the enzymes responsible for nitric oxide (NO) generation. To date, 3 distinct NOS isoforms have been identified: neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3). Biochemically, NOS consists of a flavin-containing reductase domain, a heme-containing oxygenase domain, and regulatory sites. NOS catalyse an overall 5-electron oxidation of one N^ω-atom of the guanidino group of L-arginine to form NO and L-citrulline. NO exerts a plethora of biological effects in the cardiovascular system. The basal formation of NO in mitochondria by a mitochondrial NOS seems to be one of the main regulators of cellular respiration, mitochondrial transmembrane potential, and transmembrane proton gradient. This review focuses on recent advances in the understanding of the role of enzyme and enzyme-independent NO formation, regulation of NO bioactivity, new aspects of NO on cardiac function and morphology, and the clinical impact and perspectives of these recent advances in our knowledge on NO-related pathways.

© 2005 Elsevier Inc. All rights reserved.

Abbreviations: ADMA, asymmetric dimethylarginine; ATP, adenosine triphosphate; BH₄, tetrahydrobiopterin; CAT-1, cation arginine transporter 1; cGMP, guanosine-3'5'-cyclic monophosphate; DDAH, dimethylarginine dimethylaminohydrolase; GTP, guanosine triphosphate; Hsp90, 90 kDa heat shock protein; HNO, nitroxyl; IL, interleukin; IP₃, phosphatidylinositol triphosphate; INF, interferon; NADPH, nicotinamide adenine dinucleotide phosphate, reduced form; N₂O₃, dinitrogen trioxide; NO, nitric oxide; NO⁻, nitroxyl anion; NO⁺, nitrosonium ion; NO₂, nitrogen dioxide; NO₂⁻, nitrite; NOHb, nitrosylhemoglobin; NOSIP, eNOS-interacting protein; NOSTRIN, eNOS traffic inducer; NOS, nitric oxide synthase; NOS1, neuronal nitric oxide synthase (nNOS); NOS2, inducible nitric oxide synthase (iNOS); NOS3, endothelial nitric oxide synthase (eNOS); O₂⁻, superoxide anion; O₂, oxygen; ONOO⁻, peroxynitrite; PK, protein kinase; RSNO, S-nitrosothiol species; RNNO, N-nitrosamine species; ROS, reactive oxygen species; RBC, red blood cell; sGC, soluble guanylyl cyclase; SNOAlb, S-nitrosoalbumin; SNOHb, S-nitrosohemoglobin; TNF, tumor necrosis factor.

Contents

1. Introduction	226
2. Regulation of nitric oxide synthase activity	226
2.1. Mechanisms involved in the regulation of nitric oxide synthase activity	227
2.1.1. Regulation of endothelial nitric oxide synthase activity by lipidation and subsequent localisation	227
2.1.2. Regulation of endothelial nitric oxide synthase activity by a calcium/calmodulin-dependent mechanism	227
2.1.3. Regulation of endothelial nitric oxide synthase activity by direct protein–protein interactions	227
2.1.4. Regulation of endothelial nitric oxide synthase activity by phosphorylation	232
2.1.5. Regulation of endothelial nitric oxide synthase activity by glycosylation	232
2.1.6. Regulation of endothelial nitric oxide synthase activity by modulation of substrate and cofactors availability	232

* Corresponding author. Institute of Pathophysiology, University of Essen, Hufelandstr. 55, Essen 45122, Germany.

E-mail address: rainer_schulz@uni-essen.de (R. Schulz).

2.2.	Nitric oxide synthase cofactors	232
2.3.	Endogenous nitric oxide synthase inhibitors	233
2.4.	Regulation of neuronal and inducible nitric oxide synthase expression and activities	233
3.	Developments in cellular and subcellular localisation of nitric oxide generation	233
3.1.	Nitric oxide synthase isoforms in the formed elements of the blood	233
3.2.	Cardiac nitric oxide synthase localisation	233
3.3.	Myocyte subcellular localisation of nitric oxide synthase	234
4.	Nonenzymatic nitric oxide formation	235
5.	Regulation of nitric oxide biological activity in the circulation	235
5.1.	Oxidative metabolism of nitric oxide	236
5.2.	Nitrosative metabolism of nitric oxide	236
5.2.1.	Mechanisms regulating nitrosylation	237
5.3.	Conservation of nitric oxide bioactivity and circulating nitric oxide pool	237
5.3.1.	Metabolism of nitric oxide in red blood cells	237
5.3.2.	Nitrosylation in plasma	237
5.3.3.	Alternative nitrosation pathways in plasma	238
5.3.4.	Transport of free nitric oxide in plasma	239
5.3.5.	Cellular targets of nitric oxide in tissues	239
6.	Update on the roles of constitutive nitric oxide synthase on cardiac function	239
6.1.	Neuronal nitric oxide synthase under physiological conditions	239
6.2.	Neuronal nitric oxide synthase under pathophysiological conditions	240
6.3.	Endothelial nitric oxide synthase under physiological conditions	240
6.4.	Endothelial nitric oxide synthase under pathophysiological conditions	240
6.5.	Inducible nitric oxide synthase under pathophysiological conditions	241
6.6.	Nitric oxide and irreversible tissue injury following ischemia/reperfusion	242
7.	Nitric oxide in atherosclerosis	243
8.	Clinical impact and perspectives of recent advances	243
8.1.	Diagnostic aspects	243
8.2.	New modes of nitric oxide delivery	244
8.3.	New nitric oxide–donor compounds	244
9.	Conclusions and outlook	244
	References	245

1. Introduction

Nitric oxide (NO) is a pivotal regulator of cardiovascular homeostasis. Its generation by nitric oxide synthases (NOS) has been recognised and extensively investigated for nearly a quarter of century. It is clear that the generation and actions of NO under physiological and pathophysiological conditions are exquisitely regulated and extend to almost every cell type and function within the circulation. The last 5 or 6 years have witnessed huge advances in our understanding of NO generation and actions. NO is derived not only from NOS isoforms but also from NOS-independent sources. The localisation of NO within cells and within the circulation is being extensively investigated. The regulation of the biological activity of NO after its formation and the chemistry of NO and its derivatives underpin a detailed understanding of the physiological and pathophysiological roles of NO in a number of important cardiovascular tissues. Most notably in this regard, the myocardial actions of NO have received a great deal of attention. Here, we provide an update that summarises the most significant advances in NO biochemistry and physiology during the last few years that contribute to our increasing understanding of its multi-

dimensional roles in cardiovascular homeostasis. We conclude by placing this new information within the clinical context and provide some perspectives on therapeutic applications.

2. Regulation of nitric oxide synthase activity

Three isoforms of NOS have been cloned (Balligand & Cannon, 1997; Alderton et al., 2001): the neuronal NOS (nNOS or NOS1, 150 kDa protein, encoded by the *NOS1* gene), the inducible NOS (iNOS or NOS2, 130 kDa protein, encoded by the *NOS2* gene), which is the only calcium-independent isoform, and finally, the endothelial NOS (eNOS or NOS3, 133 kDa protein, encoded by the *NOS3* gene). All isoforms are expressed in cardiovascular tissues. Constitutive NOS isoforms (NOS1 and NOS3) are specifically and highly regulated at both transcriptional (expression and abundance) and post-translational (activity and function) levels, whereas NOS2 is almost exclusively regulated transcriptionally. Positive and negative regulators of both the protein expression and activity of NOS isoforms that are largely or exclusively restricted to cardiovascular

Download English Version:

<https://daneshyari.com/en/article/9015853>

Download Persian Version:

<https://daneshyari.com/article/9015853>

[Daneshyari.com](https://daneshyari.com)